Theranostics Market: Global Industry Analysis and Forecast (2021-2027) by Therapeutic Area, Technology, End-User, and Region

Theranostics Market size was valued at US$ 80.40 Bn. in 2020 and the total revenue is expected to grow at a CAGR of 10.1% through 2021 to 2027, reaching nearly US$ 157.68 Bn.

Theranostics Market Overview:

The term theranostics refers to the use of one radioactive medicine to identify (diagnose) and another radioactive drug to give therapy to treat the primary tumour as well as any metastatic tumours. One sort of radioactive isotope, Gallium, is used in theranostics to discover or diagnose malignant targets known as tumour receptors. It then treats them with a different type of radioactive isotope called Lutetium. Global Theranostics Market To know about the Research Methodology :- Request Free Sample Report Though market forecasting through 2027 is based on real output, demand and supply of 2020, 2020 numbers are also estimated on real numbers published by key players as well all-important players across the world. Market forecasting till 2027 is done based on past data from 2016 to 2019 with the impact of global lock down on the market in 2020 and 2021.

Theranostics Market Dynamics:

As cancer occurrences continue to rise and side-effects of procedures like chemotherapy continue to be a challenge for clinicians, the theranostics market is expected to grow rapidly. Furthermore, because recovery is often protracted and requires time away from patients' daily routines, post-cancer care promises lucrative growth. The rise of tumours such as brain, kidney, liver, and breast, among others, presents a plethora of prospects for theranostics players. Growing research and development, as well as hopeful FDA approvals in the pipeline, are expected to continue to drive theranostics market growth. The high costs of therapy, as well as the fact that it is still experimental, are expected to be major restraints to the growth of the theranostics market. Furthermore, healthcare costs and a lack of information regarding post-cancer treatments are expected to be obstacles in places such as North America. Rising awareness, on the other hand, is expected to open up new chances for theranostics players. Theranostics market growth is expected to be driven by ongoing developments in cancer treatments to overcome the negative effects of current treatment approaches. The global theranostics market is being driven by the increased prevalence of chronic diseases, the demand for innovative chemotherapeutic therapies, and the need to improve disease detection. In 2017, Illumina, Inc. stated that the US Food and Drug Administration (FDA) had authorised an extended RAS panel for identifying patients who are candidates for Vectibix treatment for metastatic colorectal cancer (panitumumab). Market growth is expected to be driven by shorter medical trial times and increased collaboration between medication and diagnostics companies. In addition, the growing usage of potentially useful and clinically applicable nanomaterial’s in biological imaging and therapy is expected to boost market growth. Biocartis Group NV and Amgen Inc. teamed together in 2018 to develop a companion diagnostic test for Amgen's Veectibix medication.

Theranostics Market Segment Analysis:

Based on the Therapeutic Area, the market is segmented into Oncology, Cardiovascular Diseases, Neurological Disorders, and Immunological Disorders. Oncology segment is expected to hold the largest market share of xx% by 2027. The rising prevalence of the disease has led to an increase in the usage of cancer diagnostics to examine various types of cancer. According to the National Cancer Institute, there were 442.4 new cancer cases for per 100,000 men and women in 2017. In addition, the simple availability of the most up-to-date equipment in hospitals and diagnostics to aid in disease identification has increased demand for disease diagnosis. GE Healthcare is developing a number of imaging technologies to help doctors diagnose various cancers. The growing availability of such equipment, together with the growing elder population, has boosted the rise of oncology through these centres. Global Theranostics Market Based on the End-User, the market is segmented into Hospitals and Clinics, and Diagnostics Laboratories. Hospitals and Clinics segment is expected to grow rapidly at a CAGR of xx% during the forecast period 2021-2027. This is due to the growing number of the theranostics patients increases the Theranostics treatments in the hospitals and clinics. Global Theranostics Market

Theranostics Market Regional Insights:

North America region is expected to dominate the Theranostics market during the forecast period 2021-2027. North America region is expected to hold the largest market share of xx% by 2027. The major factor driving market growth in this region is the increased frequency of severe diseases such as neurological disorders and cancer. According to the National Cancer Institutes, 1,735,350 new cancer cases were reported in the United States in 2018. In addition, the region's market is being driven by the availability of modern healthcare infrastructure, robust R&D activities, and growing collaborations. Asia Pacific is expected to grow rapidly at a CAGR of xx% during the forecast period 2021-2027. This is due to the growing awareness and uptake of companion diagnostics, particularly for malignancies in this region. Global corporations are also putting a strong emphasis on creating partnerships and cooperation with local businesses, which is expected to drive the market growth in Asia Pacific. Qiagen and SRL Inc., a Japanese clinical lab testing firm, forged a partnership in August 2018 to introduce new companion diagnostics with fresh drug approvals. Global Theranostics Market The objective of the report is to present a comprehensive analysis of the Global Theranostics Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Global Theranostics Market dynamic, structure by analyzing the market segments and project the Global Theranostics Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Theranostics Market make the report investor’s guide.

Theranostics Market Scope: Inquire before buying

Global Theranostics Market
Report Coverage Details
Base Year: 2020 Forecast Period: 2021-2027
Historical Data: 2016 to 2020 Market Size in 2020: US $ 80.40 Bn.
Forecast Period 2021 to 2027 CAGR: 10.1% Market Size in 2027: US $ 157.68 Bn.
Segments Covered: by Therapeutic Area • Oncology • Cardiovascular Diseases • Neurological Disorders • Immunological Disorders
by Technology • Polymerase Chain Reaction (PCR) • In Situ Hybridization (ISH) • Immunohistochemistry (IHC) • Sequencing
by End-User • Hospitals and Clinics • Diagnostics Laboratories

Theranostics Market, by Region

• North America • Europe • Asia Pacific • South America • Middle East and Africa

Theranostics Market Key Players

F Hoffman La Roche • Thermo Fisher Scientific Inc. • GE Healthcare • Agilent Technologies • Qiagen NV • Foundation Medicine • Leica Biosystems Nussloch GmBH • Pfizer, Inc. • Beckman Coulter, Inc. • Focus Diagnostics • Illumina, Inc. • Abbott Laboratories • Myriad Genetics, Inc. • AmeriPath, Inc. Frequently Asked Questions: 1] What segments are covered in Theranostics Market report? Ans. The segments covered in Theranostics Market report are based on Therapeutic Area, Technology, and End-User. 2] Which region is expected to hold the highest share in the Theranostics Market? Ans. North America is expected to hold the highest share in the Theranostics Market. 3] Who are the top key players in the Theranostics Market? Ans. F Hoffman La Roche, Thermo Fisher Scientific Inc., GE Healthcare, Agilent Technologies, Qiagen NV, and Foundation Medicine are the top key players in the Theranostics Market. 4] Which segment holds the largest market share in the Theranostics market by 2027? Ans. Oncology segment hold the largest market share in the Theranostics market by 2027. 5] What is the market size of the Theranostics market by 2027? Ans. The market size of the Theranostics market is expected to reach US $157.68 Bn. by 2027. 6] What was the market size of the Theranostics market in 2020? Ans. The market size of the Theranostics market was worth US $80.40 Bn. in 2020.
1. Global Theranostics Market: Research Methodology 2. Global Theranostics Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Theranostics Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Theranostics Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Theranostics Market Segmentation 4.1 Global Theranostics Market, by Therapeutic Area (2020-2027) • Oncology • Cardiovascular Diseases • Neurological Disorders • Immunological Disorders 4.2 Global Theranostics Market, by Technology (2020-2027) • Polymerase Chain Reaction (PCR) • In Situ Hybridization (ISH) • Immunohistochemistry (IHC) • Sequencing 4.3 Global Theranostics Market, by End-User (2020-2027) • Hospitals and Clinics • Diagnostics Laboratories 5. North America Theranostics Market (2020-2027) 5.1 Global Theranostics Market, by Therapeutic Area (2020-2027) • Oncology • Cardiovascular Diseases • Neurological Disorders • Immunological Disorders 5.2 Global Theranostics Market, by Technology (2020-2027) • Polymerase Chain Reaction (PCR) • In Situ Hybridization (ISH) • Immunohistochemistry (IHC) • Sequencing 5.3 Global Theranostics Market, by End-User (2020-2027) • Hospitals and Clinics • Diagnostics Laboratories 5.4 North America Theranostics Market, by Country (2020-2027) • United States • Canada • Mexico 6. Asia Pacific Theranostics Market (2020-2027) 6.1. Asia Pacific Theranostics Market, by Therapeutic Area (2020-2027) 6.2. Asia Pacific Theranostics Market, by Technology (2020-2027) 6.3. Asia Pacific Theranostics Market, by End-User (2020-2027) 6.4. Asia Pacific Theranostics Market, by Country (2020-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Theranostics Market (2020-2027) 7.1 Middle East and Africa Theranostics Market, by Therapeutic Area (2020-2027) 7.2. Middle East and Africa Theranostics Market, by Technology (2020-2027) 7.3. Middle East and Africa Theranostics Market, by End-User (2020-2027) 7.4. Middle East and Africa Theranostics Market, by Country (2020-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Theranostics Market (2020-2027) 8.1. Latin America Theranostics Market, by Therapeutic Area (2020-2027) 8.2. Latin America Theranostics Market, by Technology (2020-2027) 8.3. Latin America Theranostics Market, by End-User (2020-2027) 8.4. Latin America Theranostics Market, by Country (2020-2027) • Brazil • Argentina • Rest Of Latin America 9. European Theranostics Market (2020-2027) 9.1. European Theranostics Market, by Therapeutic Area (2020-2027) 9.2. European Theranostics Market, by Technology (2020-2027) 9.3. European Theranostics Market, by End-User (2020-2027) 9.4. European Theranostics Market, by Country (2020-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1. F Hoffman La Roche 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Thermo Fisher Scientific Inc. 10.3. GE Healthcare 10.4. Agilent Technologies 10.5. Qiagen NV 10.6. Foundation Medicine 10.7. Leica Biosystems Nussloch GmBH 10.8. Pfizer, Inc. 10.9. Beckman Coulter, Inc. 10.10. Focus Diagnostics 10.11. Illumina, Inc. 10.12. Abbott Laboratories 10.13. Myriad Genetics, Inc. 10.14. AmeriPath, Inc.

About This Report

Report ID 91676
Category Healthcare
Published Date April 2021
Updated Date Feb 2022
Contact Us